معرفی
Michel Dorval is a Full Professor at the Faculty of Pharmacy, Université Laval, where he conducts research at the intersection of psycho-oncology, genetics, and public health. He leads a research team focused on hereditary breast cancer, palliative care, and ethical issues in genetic testing. He is the founder of Centre ROSE, now Réseau ROSE, and leads an interuniversity team on psilocybin use for existential distress in end-of-life care (www.p3a.ca).
Education:
- Baccalauréat en psychologie, Université Laval
- Maîtrise en psychologie, Université Laval
- Doctorat en épidémiologie, Université Laval
- Post-doctorat en psycho-oncologie, Dana-Farber Cancer Institute, Harvard Medical School
His research focuses on the psychosocial impact of hereditary cancer, particularly BRCA-related risks, patient decision-making, genetic counseling, and screening behaviors. He also investigates ethical and legal issues in genetic disclosure and end-of-life care. His recent work explores personalized breast cancer screening using polygenic risk scores and digital platforms. The article trends show a strong emphasis on implementation science, patient communication, and the integration of genetic services into mainstream care.
Scientific Awards:
- FRSQ Career Awards (Senior, Junior II, Junior I)
- Terry Fox Postdoctoral Fellowship
- Steve Fonyo and PNRDS Doctoral Fellowships
- Best Presentation Awards (IMPAHC 2011, Manchester 2007, ISPOR 2001)
- Collective Innovation Awards (Centre ROSE, 2014–2016)
He supervises multiple graduate students in pharmaceutical sciences and advanced pharmacotherapy. His research is funded by CIHR, CRSH, FRQS, FRQSC, Genome Canada, Genome Québec, and cancer foundations. He collaborates with institutions across Quebec and internationally. He teaches courses in research methodology and health protocols at both undergraduate and graduate levels.
Research Team and Affiliations: He leads a multidisciplinary team including research coordinators, professionals, and students. He is affiliated with the Maison Michel-Sarrazin research team and the Réseau québécois de recherche en soins palliatifs et de fin de vie (RQSPAL).
